Mr. Erez Tetro reports

VVT MED EXPANDS EUROPEAN COMMERCIAL FOOTPRINT THROUGH EXCLUSIVE DISTRIBUTION AGREEMENT IN GREECE

VVT Med Inc. has signed an exclusive distribution agreement dated June 25, 2026, for the commercialization of the company's VVT's ScleroSafe platform in Greece with General Chemical Products S.A. (GCP), an established Greek medical technology company with more than four decades of experience supporting hospitals and health care professionals through the commercialization of innovative medical devices and clinical solutions.

The distribution agreement grants GCP exclusive distribution rights for VVT's ScleroSafe platform in Greece for an initial five-year term. The distribution agreement may be terminated prior to the expiry of the initial term under customary circumstances, including for an uncured material breach, insolvency or bankruptcy of either party, failure by the distributor to satisfy certain minimum sales requirements, or where otherwise permitted under the agreement.

The distribution agreement contains minimum purchase commitments with an aggregate contractual value of approximately 712,800 euros (approximately $1.14-million based on current exchange rates) over the initial five-year term, exclusive of any purchases beyond the contractual minimum commitments.

The distribution agreement further expands VVT Med's European distribution network and establishes a commercial presence for ScleroSafe in the Greek market.

Erez Tetro, chief executive officer of VVT Med, commented: "We are pleased to enter the Greek market through our partnership with GCP. GCP's long-standing reputation and commercial infrastructure make them an excellent partner for the introduction of ScleroSafe in Greece. This agreement expands our European distribution network and supports our strategy of increasing international access to ScleroSafe. We look forward to working with GCP to introduce the technology to physicians and patients throughout Greece."

GCP is an established Greek medical technology company with more than 40 years of market presence. The company partners with international medical technology manufacturers, and provides sales, logistics, technical support and clinical services to healthcare providers across Greece.

About VVT Med Inc.

VVT Med develops, manufactures and distributes minimally invasive, non-thermal, non-tumescent solutions for the treatment of venous disease. The company's Food and Drug Administration-cleared and CE-marked technologies, including ScleroSafe and V-Block, are designed to enable office-based procedures without thermal energy or tumescent anesthesia. VVT Med's patented technology portfolio includes 55 patents from 14 patent families across 20 countries.

We seek Safe Harbor.